shutterstock_1569359980_sundry_photography

Sundry Photography / Shutterstock.com

3 February 2022Big PharmaAlex Baldwin

Gilead pays $1.25bn to GSK in HIV drug settlement

Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline (GSK) subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

Gilead to face HIV antitrust claims

5 March 2020 Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

More on this story

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

Gilead to face HIV antitrust claims

5 March 2020 Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

More on this story

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

Gilead to face HIV antitrust claims

5 March 2020 Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

More features

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

Broad Institute wins appeal to restore CRISPR patent in Europe

BMS faces fresh lawsuit over alleged cancer drug monopoly

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

Boies Schiller Flexner adds three-strong litigation team